Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Cwikla

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 24, 2001
Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curvesJ R Buscombe, J B Cwikla, B Holloway, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 21, 2000
Tc-99m MIBI in suspected recurrent breast cancerJ B Cwikla, A Kolasinska, J R Buscombe, et al.
Physics in Medicine and Biology|December 17, 2013
Three-dimensional personalized dosimetry for <sup>188</sup>Re liver selective internal radiation therapy based on quantitative post-treatment SPECT studiesS Shcherbinin, J Grimes, A Bator, et al.
Anticancer Research|May 1, 1997
Uptake of Tc-99m MIBI related to tumour size and typeJ R Buscombe, J B Cwikla, D S Thakrar, et al.
Nuclear Medicine Communications|August 1, 1997
Scintigraphic imaging of breast cancer: a reviewJ R Buscombe, J B Cwikla, D S Thakrar, et al.
Nuclear Medicine Communications|March 27, 1999
Prone SPET scintimammographyJ R Buscombe, J B Cwikla, D S Thakrar, et al.
Anticancer Research|September 3, 1999
Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancerJ B Cwikla, J R Buscombe, A D Kolasinska, et al.
Nuclear Medicine Communications|November 17, 2001
Can scintimammography with (99m)Tc-MIBI identify multifocal and multicentric primary breast cancer?J B Cwikla, J R Buscombe, B Holloway, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2009
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II studyJ B Cwikla, A Sankowski, N Seklecka, et al.
Nuclear Medicine Communications|December 16, 1998
Use of 99Tcm-MIBI in the assessment of patients with suspected recurrent breast cancerJ B Cwikla, J R Buscombe, S P Parbhoo, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 24, 2001
Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curvesJ R Buscombe, J B Cwikla, B Holloway, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 21, 2000
Tc-99m MIBI in suspected recurrent breast cancerJ B Cwikla, A Kolasinska, J R Buscombe, et al.
Physics in Medicine and Biology|December 17, 2013
Three-dimensional personalized dosimetry for <sup>188</sup>Re liver selective internal radiation therapy based on quantitative post-treatment SPECT studiesS Shcherbinin, J Grimes, A Bator, et al.
Anticancer Research|May 1, 1997
Uptake of Tc-99m MIBI related to tumour size and typeJ R Buscombe, J B Cwikla, D S Thakrar, et al.
Nuclear Medicine Communications|August 1, 1997
Scintigraphic imaging of breast cancer: a reviewJ R Buscombe, J B Cwikla, D S Thakrar, et al.
Nuclear Medicine Communications|March 27, 1999
Prone SPET scintimammographyJ R Buscombe, J B Cwikla, D S Thakrar, et al.
Anticancer Research|September 3, 1999
Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancerJ B Cwikla, J R Buscombe, A D Kolasinska, et al.
Nuclear Medicine Communications|November 17, 2001
Can scintimammography with (99m)Tc-MIBI identify multifocal and multicentric primary breast cancer?J B Cwikla, J R Buscombe, B Holloway, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2009
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II studyJ B Cwikla, A Sankowski, N Seklecka, et al.
Nuclear Medicine Communications|December 16, 1998
Use of 99Tcm-MIBI in the assessment of patients with suspected recurrent breast cancerJ B Cwikla, J R Buscombe, S P Parbhoo, et al.
Pageof 2